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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. 
INTRODUCTION
 The World Health Organization declared the novel 
coronavirus disease 2019 (COVID-19) as a pandemic in March 
2020, with rising infection rates around the world and within 
the United States.1 This outbreak has radically altered delivery 
of care in emergency departments (ED), as efforts continue to 
prevent transmission and combat the disease.2 Although attention 
has appropriately been focused on clinical management and 
emergency preparedness during COVID-19, this historic event 
has also had significant consequences for mental health that may 
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The coronavirus disease 2019 (COVID-19) pandemic caused by the coronavirus SARS-CoV-2 has 
radically altered delivery of care in emergency settings. Unprecedented hardship due to ongoing 
fears of exposure and threats to personal safety, along with societal measures enacted to curb 
disease transmission, have had broad psychosocial impact on patients and healthcare workers 
alike. These changes can significantly affect diagnosing and managing behavioral emergencies such 
as agitation in the emergency department. On behalf of the American Association for Emergency 
Psychiatry, we highlight unique considerations for patients with severe behavioral symptoms and 
staff members managing symptoms of agitation during COVID-19. Early detection and treatment of 
agitation, precautions to minimize staff hazards, coordination with security personnel and psychiatric 
services, and avoidance of coercive strategies that cause respiratory depression will help mitigate 
heightened risks to safety caused by this outbreak. [West J Emerg Med. 2020;21(4)X–X.]
be easily overlooked. Unprecedented hardship due to ongoing 
fears of exposure, threats to personal safety, and limited access 
to resources have broad psychosocial impact on patients and 
healthcare workers alike.3 These changes can significantly affect 
how individuals with behavioral symptoms may present and what 
management strategies are most appropriate during the care of 
behavioral emergencies.
Agitation is one of the most common behavioral emergencies 
in the ED, with 1.7 million episodes4 annually in emergency 
settings and a recent estimated overall ED prevalence of 2.6%.5 
Agitated patients are among the most challenging to evaluate 
and manage by emergency physicians, as their excessive 
psychomotor activity can escalate quickly into violent acts and 
physically aggressive behavior.6 Nationwide, 78% of emergency 
physicians reported being targets of workplace violence in the 
previous 12 months.7 In 2012, the American Association for 
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Emergency Psychiatry (AAEP) published Project BETA (Best 
practices in Evaluation and Treatment of Agitation), consisting 
of a landmark series of consensus guidelines to provide effective 
and safety-minded strategies for agitation management with the 
best interests of the patient in mind while ensuring the safety 
of healthcare workers.4 The Project BETA guidelines focus 
on a noncoercive approach to manage these patients with an 
emphasis on de-escalation, safety and risk assessment, and 
addressing potentially life-threatening medical concerns.8,9 Forced 
medication and physical restraint are reserved as the last resort to 
control agitation symptoms, given that their use is associated with 
elevated risk for both patients and staff.10 
The management principles encapsulated within 
Project BETA remain applicable in the COVID-19 era, but 
adaptations are needed in light of the unique circumstances 
and environmental conditions due to the pandemic. Given the 
possibility of a projected lengthy timeline before this outbreak 
abates,11 awareness of its effects on the management of agitation 
is needed now to ensure safety of both patients with behavioral 
symptoms and frontline healthcare workers caring for them. On 
behalf of AAEP, we aim to highlight in this work some important 
unique considerations for the management of agitation in the ED 
during COVID-19 (Table 1).
 
COVID-19 EFFECTS ON PATIENT VISITS AND 
PRESENTATIONS
Psychosocial Factors
The COVID-19 pandemic is occurring during a time of 
unprecedented digital interconnectedness.12 Advancements in 
digital platforms and intense media coverage have amplified 
the intensity of associated psychological fear, creating a novel 
“digital pandemic” that significantly exacerbates symptoms of 
anxiety and stress.13 The large-scale public lockdown efforts 
to implement social distancing has secondarily forced many 
individuals to stay indoors for prolonged periods of time, 
increasing the risk of social isolation, tensions within the 
home, and disruption of positive adaptive behaviors to relieve 
symptoms of mental illness.14 In addition, COVID-19 may 
directly affect workflow and slow down assessments in the ED, 
leading to escalation of agitation symptoms for those who require 
immediate attention. 
Hospital visitor restrictions reduce risk of transmission15 
but also remove vital links of social and family support for 
individuals during times of crisis. Since asymptomatic carriers 
can silently transmit the virus,16 some patients are fearful that 
they may unknowingly contract COVID-19 during their time 
in the ED. Others with symptoms concerning for COVID-19 
may escalate their behavior if their expectations for testing or 
disposition are not met due to limited capacity for EDs to widely 
test or hospitalize members of the community they serve.17 These 
added pressures can increase the risk of agitation even for visits 
that may not be associated with a behavioral chief complaint. 
With reports of recent surges in firearm sales across the US,18 
extra vigilance is needed regarding potential dangers due to 
weapons both in the healthcare setting and at home, especially for 
patients with elevated risk of self-harm or violence.19
 
Access to Services
Patients presenting with agitation often represent 
socioeconomically disadvantaged populations with 
significant health disparities.20 Unfortunately, individuals with 
homelessness, mental illness, and substance use disorders 
face additional potential problems with screening, quarantine, 
and symptom treatment during pandemics.21 Preliminary data 
demonstrating associations between mortality and challenges 
in accessing healthcare resources have already surfaced during 
COVID-19.22 Economic hardship and disruption of outpatient 
mental health services may limit the ability for these individuals 
to refill their maintenance medications for psychiatric 
and/or substance use conditions, causing exacerbation or 
decompensation of their illnesses. This is compounded by 
closure of shelters, detoxification units, and other high-density 
communal settings (eg, drop-in centers and soup kitchens) which 
may reduce their access to critical social services and increase 
their likelihood to present to the ED in need. As the support 
systems and outpatient services deteriorate for these patients, the 
likelihood that they develop decompensation of their underlying 
mental illness may increase, leading to ED visits and agitated 
behaviors during their stay.
 
Clinical Presentations
Although it may seem that increased stress and anxiety 
would inherently increase the volume of behavioral visits during 
natural disasters and pandemics, experiences from past events 
have demonstrated that the effects are quite complex and even 
counterintuitive.23 Total mental health-related visits may actually 
initially decrease as individuals focus on immediate survival 
and self-protection,24 but those who do seek care appear to have 
more severe symptoms.25 For example, inpatient psychiatric 
admissions fell by 20% for the first 30 days following the 
devastating earthquake in Christchurch, New Zealand.26 New 
psychiatric presentations following the 2011 Fukushima nuclear 
plant disaster also decreased, but those admitted had high rates 
of confusional, manic, and delirious states.27 Given the public 
perceptions of fear and mistrust around the government’s 
response to the pandemic,28 individuals with chronic psychotic 
disorders may incorporate those perceptions into their delusional 
content and manifest as themes of contamination, persecution, 
and conspiracy theories. Particular sensitivity and extra efforts to 
counteract and redirect these sentiments may be needed as part of 
the management of agitation.
In addition, there are increasing reports of neuropsychiatric 
symptoms due to COVID-19. Several case reports have 
documented encephalopathy and delirium as the presenting 
syndrome for the disease rather than the more common 
respiratory or gastrointestinal complaints.29,30 The Centers 
for Disease Control and Prevention also found that 6% of 
hospitalized patients with confirmed COVID-19 had associated 
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symptoms of altered mental status and confusion.31 Elderly 
patients are at the highest risk for morbidity and mortality related 
to the disease.32 Acute agitation in patients with delirium caused 
by hypoxia, a prominent clinical feature of patients infected 
with COVID-19, complicates the presentation of dementia and 
psychiatric illness, particularly in the older population.33 Given 
the elevated rates of clinical and adverse events associated with 
delirium and the various neuropsychiatric symptoms that may 
be associated with COVID-19,34 emergency physicians need 
to be mindful of these potential complications when evaluating 
these patients. A thorough mental status exam35 will also help 
clinicians evaluate the diverse etiologies of any acute behavioral 
presentation that may be present in this cohort of patients.   
COVID-19 EFFECTS ON CARE DELIVERY 
Individual Staff Factors
COVID-19 has taken its toll on healthcare workers amidst 
multiple additional stressors imposed upon them.36 These 
include rapid changes in clinical roles and responsibilities, extra 
workload, disrupted supplies in personal protective equipment 
(PPE), rationing of resources, and valid fears regarding potential 
exposure to the disease.3 In particular, those on the front lines 
in the ED may have increased feelings of anxiety, frustration, 
and resentment due to these added stressors in a dynamic and 
high-stress clinical environment.37 Given that de-escalation 
requires clinicians to remain calm and compassionate despite 
displays of aggression or violence, these negative emotions due 
to COVID-19 can significantly undermine efforts to use patient-
centered approaches during management of agitation.38
As emergency healthcare workers care for rising volumes of 
infected patients presenting in extremis, they work at an elevated 
risk to personal safety from potential occupational exposure 
to COVID-19.39,40 This risk increases further during episodes 
of patient agitation. Clinicians may come into close physical 
Effects on visits and presentations
Psychosocial factors • Increase in stress/anxiety symptoms exacerbated by digital media
• Public lockdown increases tensions between individuals in constant close proximity at home & disrupts 
healthy coping mechanisms
• Stress/anxiety due to banning of visitors and fear of COVID-19 exposure when in the hospital
• Extra vigilance regarding potential weapons on patients given increase in firearm purchases
Access to services • Patients are likely socioeconomically disadvantaged and suffer more during COVID-19
• Limited access to their prescribed psychiatric/substance use disorder medications
• Challenges accessing social services, detox centers, homeless shelters
Clinical presentations • Individuals with milder symptoms may refrain from coming to ED
• Patients may be in more severe forms of agitation and delirium
• Possible COVID-19 encephalopathy and delirium syndromes
• Fears regarding the pandemic may incorporate/feed into delusional content
Effects on care delivery
Individual staff factors • Staff stress/anxiety levels are high during COVID-19
• Risk to personal safety is elevated from viral transmission and may be compounded during episodes 
of physical violence
• Maneuvering, spatial orientation, awareness of safety, establishing rapport, attempting de-escalation 
can be limited by being in PPE
Clinical resource 
limitations
• Ancillary services (chaplain, social work) and psychiatric consultation (deployed elsewhere) may be 
limited during COVID-19
• Medications may be on limited supply due to increased need in ICUs (eg, sedatives)
• Lower staffing and slower responses from security personnel due to lower clinical volumes and need 
to conserve PPE
Evaluation and management recommendations to reduce/address agitation
Evaluation • Obtain collateral information early
• Perform components of the physical exam from a distance if accurate and feasible
• Don appropriate PPE and minimize number of staff in direct contact with patient
• Consider judicious use of diagnostic studies
• Lower threshold for COVID-19 testing before definitive psychiatric evaluation
Management • Pre-emptive action and extra vigilance to detect and treat early signs of agitation and escalating behavior
• Prompt and careful coordination with security personnel and psychiatric services
• Budget extra time and effort for de-escalation and non-coercive strategies
• Treat underlying cause or precipitants of delirium
• Caution with sedatives (especially benzodiazepines) and physical restraints for COVID-19+ patients
Table 1. Summary of COVID-19 effects.
ED, emergency department; PPE, personal protective equipment; ICU, intensive care unit.
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contact with COVID-19 positive patients to de-escalate, provide 
physical control of disruptive behavior, and perform diagnostic 
and therapeutic procedures. As a result, professional societies 
recommend that emergency clinicians continuously wear PPE 
during their entire shift in the ED. They also note that close 
contact during procedures or processes, including a physical 
examination, can generate potentially infectious aerosols and 
requires a higher level of PPE that includes an N95 respirator.41 
However, use of PPE may compromise the emergency clinician’s 
spatial orientation, maneuverability, and awareness of personal 
safety, which are all vital skills to safely evaluate and manage 
the agitated patient.42,43 PPE also adds physical limitations to 
recognizing facial features and body language, removing key 
aspects of nonverbal communication that support successful de-
escalation and rapport with agitated patients. 
 
Clinical Resource Limitations
In some geographic areas, EDs are overwhelmed by 
the volume of COVID-19 infected patients combined with 
critical shortages of supplies, staffing, and physical space.44 
Other EDs anecdotally report lower census levels, likely due 
to a combination of fewer accidental injuries during public 
lockdown efforts and ED avoidance behaviors by patients 
fearing exposure to the virus. As a result, staffing models have 
either decreased or adjusted to focus attention on the surges 
of COVID-19 cases45 and there may be fewer staff available 
to handle agitated patients in many EDs. In addition, security 
personnel may have extra responsibilities related to COVID-19 
(eg, visitor restrictions, minimizing traffic), impacting the 
ability for rapid and timely responses to episodes of agitation in 
the ED. Requirements to ration use of PPE46 may further limit 
the time, attention, and resources normally needed to safely 
respond to agitation. The increased number of COVID-19 
patients with critical care needs has disrupted and limited 
supplies of sedative medications in the ED.47 Ancillary services 
and psychiatric consultation are also less readily available as 
they are either furloughed to minimize exposure or deployed 
to other clinical units with more urgent needs related to the 
pandemic.17 Clinicians need to pre-emptively consider these 
limitations when managing patients at risk for agitation before 
behavior escalates and resources are needed rapidly.
 
EVALUATION AND MANAGEMENT 
RECOMMENDATIONS 
In a healthcare system that is already taxed with 
additional stressors on multiple levels, these factors unique 
to the COVID-19 era discussed above need to be taken into 
consideration to mitigate escalation to violent behavior and 
address potential threats to safety associated with agitation. 
In light of this elevated occupational hazard, extra measures 
are needed to continually protect the safety of ED personnel 
and effectively combat an anticipated lengthy battle with 
this pandemic, regardless of the clinical concerns or level of 
agitation.48 We highlight specific recommendations on the 
evaluation and management of the agitated patient in the setting 
of COVID-19.
The medical and psychiatric evaluation should proceed 
in a manner that minimizes COVID-19 exposure risk while 
effectively detecting dangerous and reversible causes of agitation. 
Collateral information should be obtained early to counteract 
limitations of history taking due to social distancing and PPE 
requirements. The Joint Statement for Care of Patients with 
Behavioral Health Emergencies and Suspected or Confirmed 
COVID-19 supports the use of telehealth for screening,49 which 
may not be applicable in every situation but can significantly 
reduce exposure. If direct contact is required, donning of 
appropriate PPE, limiting the amount of time clinicians are less 
than six feet away from the patient, and minimizing the number 
of staff members at the bedside will reduce any exposure risk.3 
The virus has been detected in the saliva of infected patients,50,51 
and precautions must be taken to minimize aerosol and droplet 
exposure, which may be magnified in those agitated patients 
who present with pressured speech or spit at ED personnel.52 
Judicious use and careful consideration of the utility in 
diagnostic studies are needed to safely evaluate for potentially 
life-threatening causes of the patient’s agitation. Finally, given 
known asymptomatic transmission of COVID-19,53 there should 
be a lower threshold to test these patients for the presence of the 
virus before admission for medical causes of their agitation or 
transferring them to definitive psychiatric care.
Project BETA strongly encourages early de-escalation, which 
combines targeted verbal and nonverbal strategies to assist the 
patient with calming down and reducing aggressive behavior.8 In 
light of COVID-19, extra vigilance and early pre-emptive action 
are needed to detect and treat any signs of agitation, including 
use of objective scales to assess the level of agitation and prompt 
de-escalation by qualified ED personnel. Extra investment in 
time and effort to develop a therapeutic relationship and establish 
trust may be needed to overcome additional patient stressors 
and physical barriers to create rapport. Clinical personnel should 
communicate early with hospital security if there is any concern 
about escalation or violent behaviors to allow for lengthier 
response times and higher potential for escalation, even in milder 
forms of agitation. Care coordination with psychiatric services 
is critical in light of limitations to outpatient mental health and 
social services. 
Patients who are delirious and acutely agitated with 
concomitant COVID-19 infection deserve special attention 
given elevated patient risks associated with the viral illness. 
Unfortunately, the ability to implement non-coercive techniques10 
and reorientation strategies54 in treatment of agitation and 
delirium is compromised by social distancing and isolation 
measures to minimize COVID-19 spread. Patients who 
experience persistent and severe agitation or delirium despite 
de-escalation and attempts to treat underlying causes or 
precipitants may require physical restraint and use of sedative 
medication therapy. It is possible that the threshold to use 
pharmacotherapy may be lower during this pandemic given the 
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elevated risk to both patients and staff caring for them. Low 
doses of first-generation antipsychotics such as haloperidol 
or second-generation antipsychotics such as olanzapine and 
risperidone have been found to be equally effective in patients 
with delirium, but have differing onset and side-effect profiles.55 
Extrapyramidal symptoms are most common with haloperidol, 
and sedation occurs most frequently with olanzapine.56 Adverse 
events associated with restraints and sedatives, including apnea 
and respiratory depression, will be significantly more dangerous 
in light of discordance between clinical and imaging evidence 
for degree of pulmonary involvement, rapid deterioration in 
the clinical course, and profound hypoxia associated with 
COVID-19.57 If these pharmacologic measures are required, the 
patient should be closely monitored with frequent vital signs and 
continuous cardiac, pulse oximetry, and capnometry monitoring. 
 
CONCLUSION
The COVID-19 pandemic has created unique stressors that 
may contribute to agitation symptoms. It has also increased 
personal risks for healthcare staff working in the ED, while 
adding new limitations to appropriately and effectively manage 
agitation due to measures needed to combat viral transmission. 
Extra measures for early detection, treatment of underlying causes 
for agitation, precautions to minimize staff hazards, coordination 
with security and psychiatric services, and avoidance of coercive 
strategies that cause respiratory depression will help mitigate 
heightened risks to safety caused by this outbreak.
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